|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, lysophosphatidylcholine and oxidized fatty acids released from oxidized low-density lipoprotein as a result of Lp-PLA(2) activity are thought to be involved in the progression of atherosclerosis.
|
10591668 |
1999 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the relationships among PAF-AH enzyme activity, genotype, age, and atherosclerosis, we assayed these parameters in a large Japanese population (n=3932) that consisted of three groups; a control group (healthy individuals; n=1684), a risk-factor group (individuals having at least one conventional risk factor for atherosclerosis; n=1398), and a diseased group (patients who had suffered a myocardial infarction or stroke; n=850).
|
10781653 |
2000 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
|
11369691 |
2001 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
|
11369691 |
2001 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discussed in this review is the accumulating evidence supporting the view that Lp-PLA2 is a potential biomarker of coronary heart disease and plays and an important proinflammatory role in the progression of atherosclerosis.
|
11963798 |
2002 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle.
|
12428682 |
2002 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle.
|
12428682 |
2002 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lp-PLA(2) is an enzyme with potentially multiple risks in atherosclerosis.
|
12865731 |
2003 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data provided no evidence that PAF-AH polymorphisms influence PAF-AH activity and atherosclerosis in hypercholesterolemic Sicilian patients.
|
15364890 |
2004 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma platelet-activating factor acetylhydrolase becomes progressively activated as atherosclerosis progresses, but lines of evidence indicate that the enzyme possesses potent antiatherogenic and antiinflammatory properties.
|
15166791 |
2004 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considerable discussion continues regarding the precise role that secreted lipoprotein-associated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylhydrolase, plays in atherosclerosis.
|
15990594 |
2005 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations provide a rationale to explore whether inhibiting Lp-PLA2 activity and consequent interference with the formation of bioactive lipid mediators will abrogate inflammation associated with atherosclerosis, produce favorable changes in intermediate cardiovascular end points (eg, biomarkers, imaging, and endothelial function), and ultimately reduce cardiovascular events in high-risk patients.
|
15731492 |
2005 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of Lp-PLA2 activity with oxLDL/LDL suggests that Lp-PLA2 may be a modulating factor in the process of atherosclerosis.
|
16438975 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the first biomarker for predicting stroke risk associated with atherosclerosis (lipoprotein-associated phospholipase A2) was recently approved by the United States Food and Drug Administration.
|
16822391 |
2006 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The association of Lp-PLA2 activity with oxLDL/LDL suggests that Lp-PLA2 may be a modulating factor in the process of atherosclerosis.
|
16438975 |
2006 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
|
16650870 |
2006 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression and purification of lipoprotein-associated phospholipase A(2), a key enzyme involved in atherosclerosis.
|
16723085 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviews the potential mechanisms by which Lp-PLA2 may participate in the pathogenesis of atherosclerosis and its clinical manifestations, namely, coronary artery disease and stroke.
|
17877917 |
2007 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In atherogenic aortas, an imbalance between PAF-AH and transacetylase activity, as well as lyso-PAF accumulation, may lead to unregulated PAF formation and to progression of atherosclerosis.
|
18587071 |
2008 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, development of antagonists or inhibitors of molecules such as peroxisome proliferator-activated receptors (PPARs), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), angiotensin-converting enzyme (ACE), angiotensin receptors and tumor necrosis factor (TNF)-alpha could be another alternative to prevent atherosclerosis.
|
19754391 |
2009 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
|
19034521 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversely, genetic deficiency of PAF-AH in defined human populations increases the severity of atherosclerosis and other syndromes.
|
18949548 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results uncover a new link between oxLDL and lp-PLA2, and may provide insight into this interaction in the context of atherosclerosis.
|
19910444 |
2010 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the lipoprotein-associated phospholipase A(2) gene (PLA2G7) in atherosclerosis remains controversial.
|
21834908 |
2011 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme which binds to oxidized LDL and has a pro-inflammatory role in the pathogenesis of atherosclerosis.
|
21870060 |
2011 |